EA201890334A1 - Твердые фармацевтические композиции для лечения вируса гепатита с - Google Patents

Твердые фармацевтические композиции для лечения вируса гепатита с

Info

Publication number
EA201890334A1
EA201890334A1 EA201890334A EA201890334A EA201890334A1 EA 201890334 A1 EA201890334 A1 EA 201890334A1 EA 201890334 A EA201890334 A EA 201890334A EA 201890334 A EA201890334 A EA 201890334A EA 201890334 A1 EA201890334 A1 EA 201890334A1
Authority
EA
Eurasian Patent Office
Prior art keywords
solid pharmaceutical
pharmaceutical compositions
pharmaceutically acceptable
hepatitis
virus
Prior art date
Application number
EA201890334A
Other languages
English (en)
Inventor
Катарин Асмус
И Гао
Коллин Гарретт
Харальд Хах
Адивараха Джаясанкар
Самуэль Киерематенг
Уте Ландер
Томас Мюллер
Мариус Нарис
Констанце Обермиллер
Регина Ройль
Катрин Шнайдер
Нэнси Сивер
Михаэль Зиимон
Бенедикт ШТАЙТЦ
Пин Тун
Ульрих Вестедт
Дунхуа Чжу
Original Assignee
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/192,211 external-priority patent/US20160375087A1/en
Application filed by Эббви Инк. filed Critical Эббви Инк.
Publication of EA201890334A1 publication Critical patent/EA201890334A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение обеспечивает твердые фармацевтические композиции, содержащие соединение 1 и соединение 2. В одном варианте осуществления твердая фармацевтическая композиция содержит (1) первый слой, который содержит 100 мг соединения 1, а также фармацевтически приемлемый гидрофильный полимер и фармацевтически приемлемое поверхностно-активное вещество, все из них составлены в аморфную твердую дисперсию; и (2) второй слой, который содержит 40 мг соединения 2, а также фармацевтически приемлемый гидрофильный полимер и фармацевтически приемлемое поверхностно-активное вещество, все из них составлены в аморфную твердую дисперсию.
EA201890334A 2015-07-17 2016-07-18 Твердые фармацевтические композиции для лечения вируса гепатита с EA201890334A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562193639P 2015-07-17 2015-07-17
US201662295309P 2016-02-15 2016-02-15
US15/192,211 US20160375087A1 (en) 2015-06-26 2016-06-24 Solid Pharmaceutical Compositions for Treating HCV
PCT/US2016/042806 WO2017015211A1 (en) 2015-07-17 2016-07-18 Solid pharmaceutical compositions for treating hcv

Publications (1)

Publication Number Publication Date
EA201890334A1 true EA201890334A1 (ru) 2018-06-29

Family

ID=57834557

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890334A EA201890334A1 (ru) 2015-07-17 2016-07-18 Твердые фармацевтические композиции для лечения вируса гепатита с

Country Status (22)

Country Link
EP (1) EP3324941A1 (ru)
JP (2) JP7133466B2 (ru)
KR (2) KR20180025317A (ru)
CN (1) CN108024964B (ru)
AU (1) AU2016296709C1 (ru)
BR (1) BR112018000982A2 (ru)
CA (1) CA2992722C (ru)
CL (1) CL2018000138A1 (ru)
CO (1) CO2018000391A2 (ru)
CR (1) CR20180088A (ru)
DO (1) DOP2018000024A (ru)
EA (1) EA201890334A1 (ru)
EC (1) ECSP18008411A (ru)
HK (1) HK1255203A1 (ru)
IL (1) IL256945B2 (ru)
MX (1) MX2018000746A (ru)
PE (1) PE20180609A1 (ru)
PH (1) PH12018500132A1 (ru)
RU (1) RU2018105849A (ru)
SG (1) SG10202002900YA (ru)
WO (1) WO2017015211A1 (ru)
ZA (1) ZA201801082B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
US20210023012A1 (en) * 2019-04-08 2021-01-28 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US8716454B2 (en) * 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
SI2498758T1 (sl) * 2009-11-13 2018-10-30 Astrazeneca Ab Formulacije dvoplastnih tablet
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
BR112013006693B1 (pt) * 2010-09-21 2022-07-12 Enanta Pharmaceuticals, Inc Compostos inibidores da serino protease hcv derivada de prolina macrocíclica
PT2897611T (pt) * 2012-09-18 2019-11-27 Abbvie Inc Métodos para tratamento da hepatite c
JP6441303B2 (ja) * 2013-03-14 2018-12-19 アッヴィ・インコーポレイテッド Ｃ型肝炎を治療するための２種の抗ウイルス剤の併用
CR20180030A (es) * 2015-06-26 2018-05-24 Abbvie Inc Composiciones farmacéuticas sólidas para el tratamiento del vhc.

Also Published As

Publication number Publication date
RU2018105849A (ru) 2019-08-19
AU2016296709C1 (en) 2022-02-24
ECSP18008411A (es) 2018-04-30
JP2018520185A (ja) 2018-07-26
RU2018105849A3 (ru) 2019-12-13
KR20180025317A (ko) 2018-03-08
DOP2018000024A (es) 2018-04-15
JP7472199B2 (ja) 2024-04-22
MX2018000746A (es) 2018-08-15
CO2018000391A2 (es) 2018-06-12
CN108024964A (zh) 2018-05-11
CR20180088A (es) 2018-05-24
AU2016296709B2 (en) 2021-11-11
WO2017015211A1 (en) 2017-01-26
JP2022141719A (ja) 2022-09-29
BR112018000982A2 (pt) 2018-09-11
EP3324941A1 (en) 2018-05-30
PE20180609A1 (es) 2018-04-09
KR20240108528A (ko) 2024-07-09
SG10202002900YA (en) 2020-05-28
JP7133466B2 (ja) 2022-09-08
CL2018000138A1 (es) 2018-07-13
IL256945A (en) 2018-03-29
CN108024964B (zh) 2022-05-03
CA2992722C (en) 2023-10-17
IL256945B2 (en) 2023-10-01
HK1255203A1 (zh) 2019-08-09
ZA201801082B (en) 2018-12-19
IL256945B1 (en) 2023-06-01
AU2016296709A1 (en) 2018-02-08
PH12018500132A1 (en) 2018-07-23
CA2992722A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
EA201890736A1 (ru) Модуляторы корового белка вируса гепатита b
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
EA201691448A1 (ru) Гибридосомы, содержащие их композиции, способы их получения и их применения
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
EA201991700A1 (ru) Селективные ингибиторы jak1
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
EA202192786A1 (ru) Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола
EA201890160A1 (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201792094A1 (ru) Ингибиторы полимеразы вируса гепатита c
EA201890334A1 (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
EA201791218A1 (ru) Композиция, содержащая ванкомицин и орлистат
EA202191343A1 (ru) Антибиотические соединения, способы их получения, фармацевтические композиции, содержащие их, и их применение